CAR-T Therapy: A Guide to Understanding the Process

Chimeric antigen receptor (CAR) T-cell therapies can potentially treat new type of cancer treatment that uses the immune system to fight cancer. CAR T involves genetically engineering T cells to express a chimeric antigen receptor targeting a specific tumor antigen. Latest developments in CAR-T cell manufacturing are efficiency-driven, scalable, and cost-effective. Reduced human error to improve throughput is a result of automation at the stage of cell processing, therefore, having faster production cycles. Modular facilities have the ability to be flexible and scaled rapidly as needed to meet demand without large capital investments.

Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00003731?utm_source=OpenPR&utm_medium=10852

CAR-T Therapy Market: Competitive Landscape and Key Developments:
1. Novartis International AG
2. Kite Pharma, Inc. (Gilead Sciences, Inc.)
3. Juno Therapeutics (Celgene Corporation)
4. Bluebird Bio, Inc. (Celgene Corporation)
5. Sorrento Therapeutics Inc.
6. Mustang Bio, Inc
7. Aurora Biopharma Inc.
8. Legend Biotech (Genscript Biotech Corporation)
9. Pfizer, Inc.
10. CARsgen Therapeutics, Ltd.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.